« Return to News | Drug Sponsors

Par to acquire Edict Pharmaceuticals

Tuesday, May 24, 2011 10:31 AM

New Jersey-based Par Pharmaceutical, which specializes in high barrier-to-entry generics and niche branded drugs, will acquire Indian generic drug maker Edict Pharmaceuticals in a deal worth up to $37.6 million in cash, according to Pharma Times.

Edict, which develops and manufactures solid oral dosage generics, has a "strong product pipeline focused on niche first-to-file, first-to-market formulations."  The company currently has seven ANDAs filed with the FDA (plus one ANDA submitted in the name of a development partner) with an additional 14 products in development.

Par's president Paul Campanelli noted that Edict's facility adds significant operational capacity and provides business continuity protection" for the firm's plant in New York. He added that the company "has a long-standing relationship" with Edict's chief executive, Muthusamy Shanmugan, "having collaborated on numerous current Par products."

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.